secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2023-07-28T23:59:59+00:00
Accession:  0000950170-23-035581
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health receives Nasdaq delisting determination due to low bid price; plans appeal and reverse split vote
--------------------------------------------------------------------------------

- Nasdaq notified Tivic that its common stock closed at $0.10 or below for 10 consecutive days; delisting determination issued.
- Company appealed; hearing set for Sept 21, 2023; trading stays during appeal process.
- Prior reverse split vote at June 2023 annual meeting failed to pass (47% of outstanding shares voted in favor, needed majority).
- July 2023 public offering included investor commitment to vote for reverse split; special meeting scheduled Aug 11, 2023.
- CEO expresses confidence in regaining compliance by mid-August; stock continues trading on Nasdaq pending hearing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017023035581/0000950170-23-035581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017023035581/tivc-20230724.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-035581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer